Astellas Pharma EMEA

24.04.2017 – 01:02
Use of Extended-Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) and Preventing Recurrence[1]
Vienna (ots/PRNewswire) - CDI, a potentially fatal disease,[2] is three times as deadly as MRSA[3],[4] and is estimated to cost the EU EUR3 billion per annum[5] New data presented today at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, demonstrate benefits of ...
mehr
21.04.2017 – 01:01
New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Additional 10,670 Bed Days a Year
Vienna (ots/PRNewswire) - CDI is one of the top ten hospital-acquired infections (HAIs) in European Hospitals[1] and is estimated to be three times as deadly as MRSA[2],[3] Data released at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017 demonstrate the impact of CDI on the ...
mehr
12.12.2016 – 08:01
Astellas Announces Transfer of Qutenza(TM) to Grünenthal
Tokyo and Chertsey, England (ots/PRNewswire) - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas"), today announced that Astellas Pharma Europe Ltd., ("Astellas Pharma Europe") has entered into a definitive agreement with Grünenthal under which Astellas Pharma Europe will transfer the exclusive rights for Qutenza(TM) (capsaicin 8% patch) in Europe, Middle East and Africa to Grünenthal. (Logo: ...
mehr
28.10.2016 – 09:16
Astellas to Acquire Ganymed Pharmaceuticals
Tokyo and Mainz, Germany (ots/PRNewswire) - - Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, "Ganymed"), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas ...
mehr
14.10.2016 – 09:01
World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
Montreal and Tokyo (ots/PRNewswire) - The World Anti-Doping Agency (President: Sir Craig Reedie, "WADA") and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka, "Astellas") today announced a global agreement to partner on the prevention of misuse and abuse of medicines for doping in sports. ...
mehr
11.04.2016 – 12:31
International Consensus Report Highlights Need for Improved Management of Clostridium difficile Infection (CDI) in Inflammatory Bowel Disease (IBD) Patients
Amsterdam, The Netherlands (ots/PRNewswire) - In patients with IBD, CDI is a key risk factor for both morbidity and mortality, with disease interactions increasing the severity of patients' colitis[1] Results from an international consensus project involving a multidisciplinary group of clinicians have been ...
mehr
04.03.2016 – 09:02
Astellas Pharma Europe Ltd. Announces New President of EMEA Operations
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma Inc. (TSE:4503), is pleased to announce that Mr Yukio Matsui has been appointed as President of EMEA Operations, with responsibility for the company's commercial operations in Europe, the Middle East and Africa. Yukio will assume his new position on 1st April 2016. Since ...
mehr
18.09.2015 – 10:01
Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP)
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd. today announced the European Commission has granted approval for a label extension for QUTENZA[TM] (capsaicin 8% patch) to include the treatment of adult diabetic patients with peripheral neuropathic pain, either alone or in combination with other ...
mehr
02.12.2014 – 11:31
Experts Attend European Parliament to Call for Urgent Action to Improve Clostridium Difficile Infection Management in Europe
Brussels (ots/PRNewswire) - Event coincides with the publication in The Lancet Infectious Diseases of EUCLID - the largest epidemiology study on Clostridium difficile infection[1] CDI Europe, the European Hospital and Healthcare Federation (HOPE) and MEP Karin Kadenbach today hosted an event at the European ...
mehr